Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 14/20 | 0.59 |
| ▸ | PGR | P06401 | 7/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120219 | 1.00 | AR (0.78) | ARNR3C1PGRCYP3A4CYP2D6 | |
| SCHEMBL19664233 | 1.00 | AR (0.78) | ARNR3C1PGRCYP3A4CYP2D6 | |
| SCHEMBL2120217 | 1.00 | AR (0.78) | ARNR3C1PGRCYP3A4CYP2D6 | |
| SCHEMBL5500186 | 0.93 | AR (0.79) | ARNR3C1PGRCYP3A4CYP2D6 | |
| SCHEMBL19674298 | 0.91 | AR (0.65) | ARNR3C1PGRCYP3A4CYP2D6 | |
| SCHEMBL2122411 | 0.90 | AR (0.76) | ARNR3C1PGRCYP3A4CYP2D6 | |
| SCHEMBL2608148 | 0.90 | AR (0.76) | ARNR3C1PGRCYP3A4CYP2D6 | |
| SCHEMBL2122412 | 0.90 | AR (0.76) | ARNR3C1PGRCYP3A4CYP2D6 | |
| SCHEMBL11892241 | 0.90 | AR (0.84) | ARNR3C1PGRESR1ESR2 | |
| SCHEMBL5500183 | 0.90 | AR (0.83) | ARNR3C1PGRCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9717739-B2 | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-01 | — | — | US | disclosed |
| US-9717739-B2 | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-01 | — | — | US | disclosed |
| US-20170202857-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-20 | — | — | US | disclosed |
| US-20170202857-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-20 | — | — | US | disclosed |
| US-20150342962-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | BAYER IP GMBH (DE) | 2015-12-03 | — | — | US | disclosed |
| US-20150342962-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | BAYER IP GMBH (DE) | 2015-12-03 | — | — | US | disclosed |
| US-8278469-B2 | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278469-B2 | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20120149670-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120149670-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120094969-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094969-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202857-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | CYP19A1, SHBG, HSD17B11 | AR 271/4885NR3C1 515/4885PGR 22/4885 |
| US-20150342962-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | CYP19A1, SHBG, HSD17B11 | AR 271/4885NR3C1 515/4885PGR 22/4885 |
| US-20120094969-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | CYP19A1, SHBG, HSD17B11 | AR 271/4885NR3C1 515/4885PGR 22/4885 |
| US-20120149670-A1 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES | CYP19A1, SHBG, HSD17B11 | AR 271/4885NR3C1 515/4885PGR 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.